The Effect of Donepezil on Glycemic Control in Type II Diabetics
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to establish the effectiveness of the drug Donepezil in treating
Type 2 Diabetes Mellitus compared to a control treatment. Donepezil is not approved by the
FDA to treat Type 2 Diabetes Mellitus and its use in this research is experimental. 50
patients with Type 2 Diabetes Mellitus (Adult Onset Diabetes Mellitus) will be randomized to
either the donepezil treatment group or the control group after screening. (25 patients in
each arm; a total of 50 patients). Both men and women shall be enrolled.Donepezil shall be
orally administered to the study group. Control group will get an orally administered placebo
which is an inert compound, lactose. Wk0 will be the randomization visit. The patients will
take the drug for 8 weeks and the last follow up visit will be the last day of week 8.